Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases

This phase II trial is studying how well fluorine F 18 sodium fluoride PET works in evaluating response to dasatinib in patients with prostate cancer and bone metastases. Diagnostic procedures, such as fluorine F 18 sodium fluoride positron emission tomography (PET), may help doctors predict a patient's response to treatment and help plan the best treatment.

PRIMARY OBJECTIVES:

I. Determine if changes in regional fluoride incorporation (SUV and Ki), as measured by fluorine F 18 sodium fluoride positron emission tomography, occur in both bone metastases and normal bone as a response to treatment with dasatinib in patients with castration-resistant prostate cancer and bone metastases.

SECONDARY OBJECTIVES:

I. Determine if changes in fluorine F 18 sodium fluoride transport (Kl) occur in both bone metastases and normal bone as a response to treatment with dasatinib in these patients.

OUTLINE: This is a multicenter study.

Patients undergo fluorine F 18 sodium fluoride PET scan at baseline and then at 12 weeks after initiation of treatment with dasatinib. PET parameters (SUV, Ki, and Kl) are also analyzed.

• Bone Metastases
• Hormone-resistant Prostate Cancer
• Recurrent Prostate Cancer
• Stage IV Prostate Cancer

Inclusion Criteria:

• Histologically confirmed prostate cancer:

  • Metastatic disease

    • Has ≥ 1 convincing bone metastasis by bone scintigraphy, CT scan/MRI, or plain x-ray
• Castration-resistant disease

• Castrate testosterone levels (< 50 ng/dL)

  • Has undergone prior orchiectomy OR is currently on maintenance luteinizing hormone-releasing hormone (LHRH) agonist or LHRH antagonist
• Scheduled to receive treatment with dasatinib on the Febbo clinical trial
• Life expectancy > 12 weeks
• Able to lie still for imaging
• Weighs ≤ 300 lbs.
• No condition that would alter mental status and preclude the basic understanding and/or authorization of informed consent
• No serious underlying condition that would otherwise impair the patient's ability to receive treatment and undergo imaging studies
• No extremely poor IV access that would preclude the placement of a peripheral IV line for injection of a radiotracer
• At least 4 weeks since prior initiation of bisphosphonate therapy
• At least 4 weeks since prior radiotherapy to the bone
• At least 4 weeks since prior radiopharmaceutical treatment to the bone
• More than 4 weeks since prior GM-CSF or G-CSF